Age X50 years has been reported to be an adverse risk factor for allogeneic BMT, and consequently many of these patients are either not transplanted or treated on nonmyeloablative protocols. To study if older patients perform poorly relative to younger adults following myeloablative allogeneic transplants, we compared the outcomes of consecutive adults aged X50 years (n ¼ 51) to those o50 years (n ¼ 262) who received BU, CY7 etoposide and allogeneic transplantation for AML, CML, MDS and NHL from 1984 to 2000. Median ages were 53 (range 50-66) and 35 (range 18-49) years for older and younger patients, respectively. Patients were low-risk if they had AML in CR1, CML in first chronic phase, refractory anemia, or NHL in remission or sensitive relapse at the time of transplantation. All others were high-risk. In patients with low-risk disease, there was no significant difference in overall survival (OS) between older and younger adults (P ¼ 0.64), while older patients tended to have a shorter OS among high-risk patients (P ¼ 0.06). The 3-year OS was 53% (95% CI, 29-77%) compared to 60% (95% CI, 50-69%) for older and younger patients with low-risk disease, respectively. The corresponding 3-year OS were 27% (95% CI, 11-43%) and 37% (95% CI, 25-45%) for high-risk patients. In low-risk patients, the incidence of acute and chronic graftversus-host disease, and treatment-related mortality were similar in older and younger patients, while older patients experienced more treatment-related deaths by day 100. On multivariable analysis, age X50 years was a significant adverse factor only when high-risk patients were considered. We conclude that when radiation-free conditioning is used, age X50 years is not a significant adverse risk factor for allogeneic BMT in patients with low-risk disease, and that such patients should not be excluded from conventional myeloablative approaches until the efficacy of nonmyeloablative transplantation is better established.
A majority of patients presenting with hematological malignancies, where allogeneic BMT is considered curative, are older than 50 years of age. 1 While some transplant centers offer myeloablative allogeneic BMT to patients above the age of 50 years, many have limited allogeneic HCT to patients less than 50, or treat such patients on nonmyeloablative protocols, based on the assumption that these patients are too old to tolerate conventional conditioning regimens. This practice is based on reports that older age is an adverse risk factor for treatment-related mortality because of graft-versus-host disease, (GvHD) infection and interstitial pneumonitis. [2] [3] [4] [5] [6] [7] These reports, however, are largely of series that included pediatric patients, where adult patients had a worse outcome, and of older studies, where current supportive care techniques were not used. More recently, studies have reported similar outcomes of allogeneic HCT for patients aged 40-50 years compared to younger patients. [8] [9] [10] [11] [12] [13] However, where patients in their sixth decade have been specifically considered, the outcome of allogeneic HCT has generally been poor. [12] [13] [14] In these studies, total body irradiation (TBI) was generally employed as a component of the conditioning regimen, and the impact of disease status at the time of transplantation on the outcome of older patients compared to younger patients was not always specifically analyzed. In this study, we compare the outcome of HLA-matched sibling allogeneic BMT in 51 patients X50 years, receiving busulfanbased non-TBI-containing regimens, to 262 younger patients transplanted during the same period of time, and specifically investigate the effect of disease status at the time of transplantation on differences in outcome between older and younger patients.
Patients and methods

Patients
The outcome of 313 adult patients, who received allogeneic BMT using non-TBI-conditioning regimens at the Ohio State University from February 1984 to July 2000, was analyzed in January 2001. The primary objective was to compare the overall survival and transplant-related mortality for patients X50 years of age with those of younger patients. Patients receiving bone marrow or peripheral blood stem cell transplants from HLA-matched or one antigen-mismatched sibling donors were included. Diagnoses included are AML, CML, myelodysplasia (MDS) and non-Hodgkin's lymphoma (NHL). Patients were stratified into 'low-risk' and 'high-risk' groups based on their disease characteristics at the time of transplantation. Low-risk patients were defined as those with AML in first CR, CML in first chronic phase, refractory anemia without evidence of excess blasts, and NHL in complete or partial remission following salvage chemotherapy. All others were considered to have 'high-risk' disease. All patients were required to have a Karnofsky performance status X60%, FEV1 and FVC X60% of predicted values, cardiac ejection fraction X40%, and serum creatinine p2 mg/dl at the time of grafting.
Only patients treated with busulfan-based conditioning regimens were included in this analysis. Patients were treated with high-dose busulfan and cyclophosphamide (BuCy2), or high-dose busulfan, cyclophosphamide, and etoposide (BuCyVP16) as previously described. 15 Unmanipulated grafts were utilized. GvHD prophylaxis consisted of cyclosporine or tacrolimus with methotrexate. Patients developing grade II-IV acute GvHD were uniformly treated with corticosteroids. All patients received prophylactic antibacterial antibiotics and antifungal agents with either low-dose amphotericin or fluconazole. Therapy with ganciclovir was routinely instituted when there was evidence of reactivation of CMV on weekly surveillance viral blood cultures.
Statistical analysis
Baseline clinical characteristics were compared for patients aged X50 years and o50 years using the w 2 test or Fisher's exact test for categorical variables, and the Mann-Whitney test for continuous variables. 16 For the analysis of OS and cumulative incidence of relapse, patients were stratified according to 'low-risk' or 'high-risk' as defined above. OS was calculated from the time of transplant using the Kaplan-Meier method. 17 The cumulative incidence of relapse or progression (for cases of NHL) was calculated from the time of transplant using the Kaplan-Meier method, censoring for patients alive in continuous remission and for deaths in the absence of progression. Survival curves for OS and cumulative incidence of relapse/ progression were compared using the log-rank test. 17 The incidence of acute GvHD, interstitial pneumonitis, and transplant mortality rates for patients X50 years were compared to those of patients o50 years old using the w 2 test. To better study the potential independent effect of age and other factors on OS, Cox proportional hazard models were constructed separately for both low-and high-risk patients. 18 For all analyses, a two-sided a-value of 0.05 was considered significant. Statistical analyses were performed using SPSS version 10.0.
Results
Patient characteristics
The median age of the older patients was 53 (range 50-66) years, with 16 patients aged 55-59 years, and four patients aged 60 years or older. The median age of younger patients was 35 (range 18-49) years. The baseline clinical characteristics of these patients are shown in Table 1 . A significantly higher proportion of patients X50 years had an MDS compared to patients o50 years (29 vs 7%, Po0.001), while a significantly higher proportion of younger patients were transplanted for AML (26 vs 41%, P ¼ 0.04). The majority of patients in both age groups received full HLAmatched transplants. Two of 15 (3.9%) patients aged X50 years and 14 of 262 (5.3%) younger patients received transplants from one antigen-mismatched sibling donor. There was no significant difference in the interval between diagnosis and transplantation, or in the distribution of disease risk between older and younger patients. A total of 41% of patients X50 years were considered 'low-risk' compared to 46% of patients o50 years of age (P ¼ 0.65). A significantly lower proportion of patients aged X50 years received BuCy2 compared to younger patients (47 vs 80%, Po0.001). As older patients were more likely to be transplanted in the latter years of this study, the median follow-up for surviving patients X50 years was 3.0 (range 1-5.7) years, significantly shorter than the median followup of 5.8 (range 0.1-16.7) years for younger patients (Mann-Whitney test, P ¼ 0.001).
OS of patients X50 years compared to younger patients
Overall, there was a trend for shorter OS for patients X50 years although this did not reach statistical significance (P ¼ 0.06; Figure 1a ). However, as the difference in outcome between older and younger patients may vary according to disease status at the time of transplantation, we analyzed separately the OS for older and younger patients in each disease-risk category. In patients with lowrisk disease, there was no difference in OS between older and younger patients (Figure 1b) . The median OS for lowrisk patients aged X50 years was not reached, and that of patients o50 years was 10.7 years (P ¼ 0.64). At 3 years, the actuarial OS for patients aged X50 years was 53% (95% confidence interval (CI), 29-77%), compared to 60% (95% CI, 50-69%) for younger patients. Older patients with high-risk disease, however, had a worse outcome compared to younger patients with similar disease risk (Figure 1c) . The median OS for high-risk adults X50 years was 0.3 years compared to 0.9 years for younger patients (P ¼ 0.05). Similarly, the 3-year OS for older high risk was 27% (95% CI, 11-43%) compared to 37% (95% CI, 29-45%) for younger patients. There was no significant difference in the cumulative incidence of relapse or progression for patients X50 years compared to younger patients (P ¼ 0.96) ( Figure 2 ). This was also true when patients were stratified by risk category (low-risk, P ¼ 0.88; high-risk, P ¼ 0.94). As there was an imbalance in the distribution of disease type in older and younger patients, the outcomes of older and younger patients in each disease category were compared. There were no significant differences in the survival outcomes of AML and CML patients aged X50 years compared to younger adults (P ¼ 0.84 and 0.51 for AML and CML, respectively). At 3 years, the OS for AML (Figure 3a) . Similarly, the 3-year OS for CML patients X50 years was 60% (95% CI, 29-83%) compared to 56% (95% CI, 50-69%) for younger patients (Figure 3b) . However, as shown in Figures 3c and 3d , in spite of similar proportions of low-and high-risk patients in each disease category, older patients with MDS and NHL tended to have worse outcomes than younger patients, although this did not reach statistical significance (P ¼ 0.07 and 0.30 for MDS and NHL patients, respectively).
Incidence of acute and chronic GvHD, and interstitial pneumonitis Table 2 summarizes the incidence of acute and chronic GvHD, and interstitial pneumonitis in patients aged X50 years compared to younger adults. Of 46 evaluable patients aged X50 years and 259 evaluable patients o50 years, 19 and 94 developed grade II-IV acute GvHD, respectively (P ¼ 0.52). Furthermore, there was no difference in the severity of acute GvHD as assessed by the relative incidence of grade II-IV disease in older and younger patients. Similarly, in 33 and 216 older and younger patients evaluable for chronic GvHD, respectively, there was no significant difference in the incidence of extensive stage chronic GvHD (36 vs 39%, P ¼ 0.49), although limited stage disease occurred more frequently among older patients (36 vs 19%, P ¼ 0.04). The incidence of interstitial pneumonitis was similar in patients aged X50 and o50 years (12 vs 15%, P ¼ 0.52). Importantly, when low-and high-risk patients were analyzed separately, no differences between older and younger patients were observed in the incidence of acute grade II-IV GvHD (low-risk, P ¼ 0.21; high-risk, P ¼ 0.85), extensive chronic GvHD (low-risk, P ¼ 0.36; high-risk, P ¼ 0.62) or interstitial pneumonitis (low-risk, P ¼ 1.00; high-risk, P ¼ 0.16).
Treatment-related mortality
To further investigate the effect of disease status at transplantation on the outcome of older and younger patients, we analyzed the treatment-related mortality at days 30 and 100 post transplantation. Overall, treatmentrelated mortality was higher at days 30 and 100 post transplantation for patients X50 years, although this reached statistical significance only at day 100 (35 vs 18%, P ¼ 0.007). Analysis of treatment-related mortality by disease status indicated that the higher mortality among older patients, compared to younger patients, was largely confined to those who had high-risk disease at the time of transplantation (Table 3) . High-risk patients experienced higher treatment-related mortality at day 30 (17 vs 6%, P ¼ 0.07), which reached a significant level by day 100 (47 vs 24%, P ¼ 0.023). In contrast, treatment-related mortality was similar at day 30 (0 vs 2%, P ¼ 1.00) and day 100 (19 vs 10%, P ¼ 0.26) among older and younger patients with low-risk disease. The difference in mortality between older and younger patients with high-risk disease was mostly because of regimen-related toxicity and sepsis rather than severe acute GvHD or interstitial pneumonitis (see above).
Multivariable analysis of factors affecting OS in low-and high-risk patients
As disease status at the time of transplantation appeared to have a greater impact on the outcome of patients X50 years compared to younger patients, the independent significance of age was investigated in multivariable stepwise Cox regression analysis separately for low-and high-risk patients. Variables analyzed were age (X50 vs o50 years), disease type, period of transplantation (1984-1990 vs 1990-2000) , time from diagnosis to transplant (p1 vs 41 year) and conditioning regimen (BuCy2 vs BuCyVP). The results of the Cox regression analyses are summarized in Table 4 . While age X50 years emerged as the only significant adverse prognostic factor in high-risk patients (P ¼ 0.04), among low-risk disease patients, the only significant variable affecting survival was disease type (P ¼ 0.046). Importantly, age X50 was not a significant factor affecting survival of low-risk patients (P ¼ 0.54), together with other variable, including period of transplantation (P ¼ 0.34), conditioning regimen (P ¼ 0.88) and transplantation within 1 year of diagnosis (P ¼ 0.66).
Discussion
Recent studies have suggested similar outcomes of allogeneic BMT in patients aged 40-50 years compared to younger patients. [8] [9] [10] [11] [12] [13] Less data are available on the outcome of patients X50 years, although generally the reported outcome has been poor. [12] [13] [14] As a result, some programs either limit allogeneic BMT to patients o50 years or utilize nonmyeloablative approaches for these patients on the assumption that these patients are less able to tolerate conventional myeloablative allogeneic transplants. However, the potential contributions of disease status at the time of transplantation, particularly the presence of advanced or refractory disease, and the conditioning regimen used, to the observed differences in outcome of older patients have not been extensively investigated. In this study, we demonstrate that by using myeloablative radiation-free, busulfan-based conditioning, low-risk disease patients X50 years can achieve outcomes similar to younger adults with comparable disease characteristics.
An important finding of our study is that disease status at the time of transplantation is an important variable when the age of patients undergoing allogeneic HCT is considered. While the outcome of low-risk patients X50 years was very similar to that of younger adults with low-risk disease, older patients with high-risk disease had an inferior outcome to that of younger high-risk patients. The difference was because of the increased early (day 100) regimen-related toxicity in older patients with high-risk disease rather than a higher incidence of relapse or severe GvHD or IP. As high-risk patients are more likely to be extensively pretreated, the worse outcome of older patients in this group may reflect a significant reduction in organ reserve with age, predisposing to more serious regimenrelated toxicity. This result confirms an earlier analysis of 2180 patients reported to the International Bone Marrow Transplant Registry, which included 80 patients X50 years, where treatment-related mortality was higher only in patients X50 years (relative risk 2.35). 13 The extent to which our use of radiation-free conditioning may have contributed to the equivalent outcome in older and younger patients with low-risk disease is uncertain. Randomized studies comparing BU-CY and CY-TBI in AML and CML patients have suggested equivalent results for both regimens. [19] [20] [21] [22] However, the latter studies included predominantly young patients (median ages 32-37 years) and only rarely patients X50 years. Indeed, the outcome of patients aged X50 years has generally been poor when TBI-based regimens have been exclusively used. In two studies, where TBI-based regimens were used, the survival of patients older than the age of 50 years was rare, largely because of a high mortality from pulmonary toxicity and GvHD. 12, 14 These results contrast sharply with ours where the incidence of severe acute GvHD and IP are markedly less in older patients, and sustained survival is much more favorable. While other factors may have contributed to these differences, the high incidence of fatal pulmonary toxicity in the latter reports suggests that TBI may be an important factor. 23 Our results also contrast with other reported series where a significant proportion of patients were also treated with radiation-free regimens. 11, 24 In a report by Du and colleagues, 24 where 80% of patients received radiation-free conditioning, age 450 years was an independent adverse factor for survival on multivariable analysis. Patients who received radiation-free regimens, however, were not analyzed separately and the preparative regimen was not considered in the analysis. It is unknown, therefore, if age 450 years would have emerged as a significant variable if only radiation-free regimens were considered. While our results raise the possibility that the equivalent outcomes of allogeneic HCT observed for older and younger low-risk adults may be partly influenced by the preparative regimen, we do not exclude the possibility that similar results may also be obtained with radiation-based regimens.
There is increasing interest in the use of nonmyeloablative regimens for allogeneic HCT, based on the recognition that marrow ablation is not required for successful engraftment. 25, 26 Early studies suggest that regimen-related toxicity may be significantly reduced permitting the extension of allogeneic transplantation to patients aged up to 70 years or more. 27, 28 While these results are encouraging, long-term disease control, particularly of more aggressive disorders such as AML and aggressive NHL, remains to be determined. Our results indicate that many patients X50 years with low-risk disease can fare well with conventional allogeneic transplantation, and the general assumption that older patients cannot tolerate myeloablative regimens and should therefore be considered for nonmyeloablative approaches may not be valid. In patients with high-risk disease, however, the outcome for older patients appears to be worse than that of younger adults, and it is less certain that nonmyeloablative approaches will be suited to many of these patients with refractory and advanced disease. Novel approaches are needed for this group of older adults. We conclude that age alone should not be the deciding factor in the decision to proceed to myeloablative transplantation in patients X50 years, particularly in those with low-risk disease.
